| Patent(s) and the Corresponding Patented Drug(s) |
Top |
| World Intellectual Property Organization (WIPO) |
| Patent ID |
WO2014170706 |
| Title |
Galloyl Benzamide-Based Compounds As Jnk Modulators. |
| Abstract |
The present invention relates to the use of compounds having a galloyl benzamide structure in the treatment and/or prevention of medical conditions mediated through c-Jun N-terminal kinases (JNKs) and to pharmaceutical compositions comprising said compounds. |
| Applicant(s) |
Universit Degli Studi Di Bari |
| Patent ID |
WO2001027268 |
| Title |
Cell-Permeable Peptide Inhibitors of The Jnk Signal Transduction Pathway. |
| Abstract |
The invention provides cell-permeable peptides that bind to JNK proteins and inhibit JNK-mediated effects in JNK-expressing cells. |
| Applicant(s) |
University of Lausanne |
| Representative Drug(s) |
D03MTX |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2011071491 |
| Title |
Isotopologues of 4-[9-(Tetrahydro-Furan-3-Yl)-8-(2, 4, 6- Trifluoro-Phenylamino)-9H-Purin-2-Ylamino]-Cyclohexan-1-Ol. |
| Abstract |
Provided herein are isotopologues of Compound 1, which are enriched with isotopes such as, for example, deuterium. Pharmaceutical compositions comprising the isotope-enriched compounds, and methods of using such compounds are also provided. |
| Applicant(s) |
Signal Pharmaceuticals |
